What Foresite Labs does

Foresite Labs, LLC is a San Francisco–based AI and data science company incubation platform founded in 2019 by Jim Tananbaum and Vik Bajaj, operating as the operational arm of the broader Foresite organization alongside Foresite Capital (founded 2011, ~$3.5B AUM). The firm identifies scientific and technological opportunities—primarily at the intersection of AI, life sciences, and increasingly the physical economy—and recruits founders to co-build companies, supplying capital, scientific infrastructure, data resources, and operational support through incubation. Its platform integrates AI, data science, and advanced analytics to analyze large-scale clinical, genomic, and multi-omics datasets, with a standardized data ecosystem that compounds learnings across ventures.

Notable incubated companies include Prometheus (AI for the physical economy, co-incubated with Arch Ventures in 2024, $41B valuation by June 2026 with Jeff Bezos as co-CEO), Xaira Therapeutics (AI drug discovery, $1B Series A in April 2024), Alumis (TYK2 inhibitors for autoimmune disease, NASDAQ: ALMS, $345.1M IPO), and Candid Therapeutics (T-cell engagers for autoimmune disease, acquired by UCB in May 2026). Foresite Labs also operates a dedicated $173M fund (launched March 2022) to back portfolio companies, and maintains offices in San Francisco and Boston with a team of approximately 18 scientists, engineers, and operators.

The business model is venture-studio returns: equity creation and appreciation in incubated companies, realized through IPOs, acquisitions, and subsequent financings, supplemented by management fees on the dedicated fund. Foresite Labs does not sell products or services to external customers; rather, it distributes its capabilities through direct partnerships with founders it recruits and co-invests alongside financial partners such as Arch Ventures and Foresite Capital.

Name

Foresite Labs

Legal name

Foresite Labs, LLC

Website

https://foresitelabs.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Foresite Labs is an AI and data science company incubation platform founded in 2019 that co-builds transformative ventures in life sciences and the physical economy alongside founders, supplying capital, scientific infrastructure, and operational support through a dedicated $173M fund.

Ownership category

akta.pro rank

Product category

Biotech Incubation Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

akta.pro secondary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Biotech incubation platform
• AI drug discovery
• Venture studio services
• Company formation platform
• Data science incubation

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Portfolio Company Success: Foresite Labs generates returns through successful exits and appreciation of equity stakes in incubated companies. The firm provides incubation services, capital, and operational support to early-stage ventures, with returns realized through IPOs, acquisitions, or subsequent funding rounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Foresite Labs operates an AI- and data-science-driven company incubation platform that identifies scientific opportunities, recruits visionary entrepreneurs, and provides capital, scientific infrastructure, data capabilities, and operational support to co-found and scale transformational companies. Its portfolio spans AI-powered drug discovery (Xaira Therapeutics), autoimmune therapeutics (Alumis, Candid Therapeutics), and AI for the physical economy (Prometheus). The firm monetizes through equity appreciation and successful exits of incubated companies.

Product overview

Foresite Labs operates as an AI and data science-focused company incubation platform supporting visionary entrepreneurs building transformative companies across healthcare and life sciences. The platform provides three core capabilities: (1) a team of scientists, engineers, and operators who partner to build companies in AI, science, and technology; (2) integrated AI, data science, and advanced analytics capabilities to extract deeper insights and drive innovation; and (3) a data ecosystem that standardizes and harmonizes data generation and analysis across the portfolio. The platform has incubated notable companies including Prometheus (AI for physical economy, $41B valuation), Xaira Therapeutics (AI-powered drug discovery, $1B Series A), Candid Therapeutics (autoimmune T-cell Engagers, acquired by UCB), and Alumis (TYK2 inhibitors for autoimmune diseases, NASDAQ:ALMS). The company believes AI will greatly accelerate the pace of human discovery and innovation.

Differentiator

Problem solved

Functional benefit

Products and services

• Foresite Labs Incubation Platform An AI- and data-science-driven company formation and incubation platform that supports visionary entrepreneurs building transformative companies. Integrates AI, data science, and advanced analytics with experimental techniques to accelerate scientific discovery and company growth; intended for scientific founders seeking capital, data infrastructure, and operational support.
• Xaira Therapeutics AI-powered drug discovery company incubated at Foresite Labs, applying AI to learn the language of life and transform how diseases are treated. Released the largest Perturb-Seq dataset in June 2025 to power its Virtual Cell model.
• Alumis

Quantifiable outcome

• Prometheus reached $41 billion valuation within 2 years of incubation
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foresite Labs